Form 4: REGENXBIO Director Acquires Shares and Options

REGENXBIO Inc. reports that Director Alexandra Glucksmann acquired 9,807 shares of common stock and was granted options for 46,600 shares.

Summary

• Alexandra Glucksmann, a Director at REGENXBIO Inc., acquired 9,807 shares of common stock on May 29, 2026.
• These shares were acquired as part of a restricted stock unit (RSU) award, with 100% vesting on May 29, 2027, contingent on continued service.
• Additionally, Glucksmann was granted stock options to purchase 46,600 shares of common stock at an exercise price of $7.01.
• These options are set to vest on May 29, 2027, also subject to continued service.
• Following these transactions, Glucksmann beneficially owns 28,861 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it reflects a standard compensation and incentive mechanism for a director, indicating continued engagement.

Positives

• Director Alexandra Glucksmann's acquisition of shares and options indicates continued commitment and alignment with the company's performance.
• The RSU award and stock options vest over time, incentivizing long-term service and performance.
• The acquisition of common stock directly by a director can be viewed positively by investors as a sign of confidence in the company's future.

Risks

• The vesting of RSUs and stock options is contingent on the continuous service of the recipient, implying a risk of forfeiture if service is terminated before the vesting date.
• The value of the acquired shares and options is subject to market fluctuations and the future performance of REGENXBIO Inc.

Future Outlook

The future outlook for the acquired shares and options is tied to the continuous service of Alexandra Glucksmann and the future performance of REGENXBIO Inc. stock, with full vesting expected on May 29, 2027, and option expiration on May 29, 2036.

Industry Context

StockSavvy.ai notes that director stock acquisitions, particularly through RSU awards and option grants, are common within the biotechnology sector as a means to attract and retain key leadership talent and align their interests with shareholders.

Stakeholder Impact

• Shareholders: The acquisition by a director can be seen as a positive signal of confidence, potentially influencing investor sentiment.
• Employees: The compensation structure highlights the company's strategy for retaining key personnel through long-term incentives.
• Management: Reinforces the alignment of management's interests with those of the company and its shareholders.

Next Steps

• Continuous service by Alexandra Glucksmann until May 29, 2027, for full vesting of RSUs and stock options.
• Potential exercise of stock options after vesting, subject to market conditions and company performance.

Key Dates

Keywords

REGENXBIO Inc., RGNX, Form 4, Director, Stock Options, Restricted Stock Units, Share Acquisition, Beneficial Ownership, SEC Filing